Navigation Links
SuperGen Reports 2008 First Quarter Financial Results
Date:4/28/2008

ompany recognizes royalty revenue on a cash basis when it is received. The Company also expects to record additional milestones that relate to the sale of products to Mayne Pharma that are estimated in a range from $1.6 million to $2.6 million. No other cash flows resulting from business development transactions are currently reflected in the 2008 financial guidance. Research and development expenses for 2008 are expected to total approximately $34 million to $36 million with the growth over 2007 influenced by increasing costs related to clinical trial programs such as MP-470, ongoing pre-clinical product development efforts and increasing investment in the discovery, pre-clinical, manufacturing, regulatory and clinical development operations of the Company. The Company expects to record a non-cash charge during 2008 of approximately $5.2 million for acquired in-process research & development resulting from a milestone payment to the former Montigen stockholders. This payment is contingent on the filing of an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) of a second drug emanating from the acquired technology. Selling, general and administrative expenses for 2008 are expected to total approximately $13.5 million. Included in the 2008 total operating expenses are non-cash stock-based compensation expenses of approximately $4 million. Based on the revised 2008 financial guidance the Company is estimating a loss from operations in a range of between $17 million to $19 million. The Company expects average shares outstanding for 2008 to be approximately 58 million common shares.

Recent Corporate Events:

-- April 2008: The Company had multiple abstracts accepted for oral and

poster presentation at the American Association of Cancer Research

(AACR) Annual Meeting, which took place April 12-16 in San Diego,

California. Highlights of the presentations are included below:

-- SG
'/>"/>

SOURCE SuperGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
2. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
3. SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008
4. SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
5. SuperGen to Announce 2008 First Quarter Financial Results April 28, 2008
6. SuperGen to Webcast 3rd Annual Analyst Day on April 29, 2008
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. QMed, Inc. Reports July Medicare SNP Enrollments
9. Phlo Affiliate Reports Expanded Coverage to Oregon Border
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... 1, 2015 Goldman Small Cap Research, a ... and microcap sectors, announced today that it has issued ... PMCB), a publicly traded clinical stage biotechnology company focused ... To view the sponsored research article, along with disclosures ... please visit www.GoldmanResearch.com .  In ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 Proove ... Personalized Medicine , presented two scientific posters at the ... last week. The four-day event was hosted at the ... specialists dedicated to educating genetic and genomic professionals on ... Genetics and Insomnia: Study on the Role of DAT1 ...
(Date:4/1/2015)... Canada,s Research-Based Pharmaceutical Companies (Rx&D) acknowledges ... on Cost Drivers of Public Drug Plans in ... the rates of change in drug costs have been steadily ... in 2012/13 for a number of select public drug plans. ... of medicines without considering their overall impact on the system ...
(Date:4/1/2015)... and NEW YORK , ... (NASDAQ:  PTBI), a biopharmaceutical company advancing protein biologic ... an overview of the Company,s 2014 achievements and ... below demonstrate the progress the Company has made ... corporate partnerships for its MuGard programs, the FDA ...
Breaking Biology Technology:Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech 2Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech 3Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech 4Proove Biosciences Presents Research Studies at Annual Clinical Genetics Meeting 2015 2Rx&D responds to PMPRB report: overall impact of medicines must always be considered 2PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 2PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 3PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 4PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 5PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 6
... / PRNewswire / -- Cognition Therapeutics Inc., a drug ... has closed on a $2.5 million Series A1 financing it ... to Investigational New Drug (IND) candidate status. The round was ... investing groups, and was syndicated with Tech Coast Angels.   ...
... new image and cell technologies have for the first ... red blood cells. The researchers, from the Walter and ... of Technology, Sydney (UTS), achieved this long-held aim using ... a technology platform new to Australia. The detailed ...
... Gen-Probe Incorporated (Nasdaq: GPRO ) announced today that ... 2010 financial results on Tuesday, February 15, 2011 at approximately ... by a conference call with management at 4:30 p.m. ET. ... and may be accessed on the investors section of the ...
Cached Biology Technology:Cognition Therapeutics Completes $2.5M in Series A1 Financing to Advance Alzheimer's Disease Drug Treatment Program 2Cognition Therapeutics Completes $2.5M in Series A1 Financing to Advance Alzheimer's Disease Drug Treatment Program 3Malaria parasite caught red-handed invading blood cells 2Malaria parasite caught red-handed invading blood cells 3Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2010 Earnings Conference Call 2
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ... - Global Strategic Business Report" report to their offering. ... Biometrics in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Latin America . Annual estimates ...
(Date:3/17/2015)... NEW YORK , March 17, 2015 /PRNewswire/ ... , the largest exhibition for service robots ever ... . RoboUniverse takes place on May 11-13, 2015 ... Sponsors and exhibitors for the event include: Acorn ... Motion Control; EZ-Robot; Infranor; Kinova Robotics; Littler; NewBotic ...
(Date:3/12/2015)... , March 12, 2015 WHEN:Tuesday, March ... Registration here: http://bit.ly/1G7Os0L . SPEAKERS: , Frost ... SeshagiriPhoto - http://photos.prnewswire.com/prnh/20150311/181111 Biometric ... to compete in several different markets and industries. ... currently witnessing an uptrend. Join ...
Breaking Biology News(10 mins):Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3
... results in irreversible damage to the heart that ... results from the limited ability of the myocardium ... from Tufts University now document the existence of ... stem cells with therapeutic potency for myocardial tissue ...
... The World Health Organization (WHO) warned about increased ... dengue fever across tsunami-affected areas in Southeast Asia. ... region on 26 December, the organization is strengthening ... for mosquito vectors to multiply to sufficient levels, ...
... potentially dangerous chemical has been found by Health Canada ... processed foods, especially canned or bottled foods. A new ... student Carolina Perez Locas explains the presence of this ... The study, published in the October, 2004 issue of ...
Cached Biology News:WHO Warns Of Increased Risk Of Vector-borne Diseases In Tsunami-affected Areas 2WHO Warns Of Increased Risk Of Vector-borne Diseases In Tsunami-affected Areas 3WHO Warns Of Increased Risk Of Vector-borne Diseases In Tsunami-affected Areas 4
...
Convenient 10X buffer concentrate used to maximize binding to the solid phase in microwell ELISA. Formulated to provide optimal pH and ionic strength for binding of antibodies and some antigens. Co...
... making flow cytometry accessible to anyone in the ... latest addition to Guavas on-demand microcapillary flow cytometry ... to use, surprisingly affordable, very compact, and nicely ... The Guava EasyCyte Mini has all of the ...
... systems provide automated, higher throughput screening of ... tubes. This flexible sample format makes the ... basic research, target validation, assay development, and ... the Guava PCA-96 uses a green laser ...
Biology Products: